Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network
- PMID: 40263541
- PMCID: PMC12572384
- DOI: 10.1038/s41418-025-01513-8
Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network
Abstract
TP53, the most frequently mutated gene in human cancer, encodes a transcriptional activator that induces myriad downstream target genes. Despite the importance of p53 in tumor suppression, the specific p53 target genes important for tumor suppression remain unclear. Recent studies have identified the p53-inducible gene Zmat3 as a critical effector of tumor suppression, but many questions remain regarding its p53-dependence, activity across contexts, and mechanism of tumor suppression alone and in cooperation with other p53-inducible genes. To address these questions, we used Tuba-seqUltra somatic genome editing and tumor barcoding in a mouse lung adenocarcinoma model, combinatorial in vivo CRISPR/Cas9 screens, meta-analyses of gene expression and Cancer Dependency Map data, and integrative RNA-sequencing and shotgun proteomic analyses. We established Zmat3 as a core component of p53-mediated tumor suppression and identified Cdkn1a as the most potent cooperating p53-induced gene in tumor suppression. We discovered that ZMAT3/CDKN1A serve as near-universal effectors of p53-mediated tumor suppression that regulate cell division, migration, and extracellular matrix organization. Accordingly, combined Zmat3-Cdkn1a inactivation dramatically enhanced cell proliferation and migration compared to controls, akin to p53 inactivation. Together, our findings place ZMAT3 and CDKN1A as hubs of a p53-induced gene program that opposes tumorigenesis across various cellular and genetic contexts.
© 2025. The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare.
Conflict of interest statement
Competing interests: RM is on the Advisory Boards of Kodikaz Therapeutic Solutions, Orbital Therapeutics, Pheast Therapeutics, 858 Therapeutics, Prelude Therapeutics, Mubadala Capital, and Aculeus Therapeutics. RM is a co-founder and equity holder of Pheast Therapeutics, MyeloGene, and Orbital Therapeutics. The other authors declare no competing interest. Ethics: All animal experiments were performed in accordance with the Stanford University Administrative Panel on Laboratory Animal Care (protocol number 10382) guidelines and regulations. Mice (Mus musculus) were maintained at Stanford University’s Comparative Medicine Pavilion and Research Animal Facility according to practices prescribed by the National Institutes of Health and the Institutional Animal Care and Use Committee (IACUC). The Association for Assessment and Accreditation of Laboratory Animal Care provides additional accreditation to Stanford University.
Update of
-
Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.bioRxiv [Preprint]. 2024 Sep 18:2024.09.17.612743. doi: 10.1101/2024.09.17.612743. bioRxiv. 2024. Update in: Cell Death Differ. 2025 Nov;32(11):1954-1969. doi: 10.1038/s41418-025-01513-8. PMID: 39345444 Free PMC article. Updated. Preprint.
References
-
- Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002;19:607–14. - PubMed
MeSH terms
Substances
Grants and funding
- T32 CA009302/CA/NCI NIH HHS/United States
- T31DT1713/Tobacco-Related Disease Research Program (TRDRP)
- R35CA197591/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R35 CA197591/CA/NCI NIH HHS/United States
- T32CA009302/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
